Millions of people all over the world have diseases for which there is no known treatment. For Laurantis researchers, management, and investors, those with unmet medical needs serve as our reminder that breakthrough treatments are good for society and good for business.
Laurantis Pharma Oy is a specialty pharmaceutical company developing first-in-class products for inflammation and cancer.
Based on two proprietary technologies (cis-UCA and Ad-VEGF-C), our pipeline is focused on addressing unmet needs in atopic dermatitis, dry eye, bladder cancer, and secondary lymphedema.
Laurantis Pharma’s lead candidate is a non-steroidal emulsion cream for atopic dermatitis that is derived from our cis-UCA–based proto dynamic therapy.